12 results about "Hepatitis B infection" patented technology

To identify novel nucleic acid molecules that can inhibit the expression of both PAPD5 and PAPD7 in vivo and in vitro.SOLUTION: The present invention provides a nucleic acid molecule that is complementary to both PAP-related domain-containing 5 (PAPD5) and PAP-related domain-containing 7 (PAPD7), and inhibits the expression of both PAPD5 and PAPD7 when using a single nucleic acid molecule. The present invention also provides PAPD5 and PAPD7 specific nucleic acid molecules used for the treatment and / or prevention of HBV infections, especially chronic HBV infections. Also included in the present invention are pharmaceutical compositions for use in the treatment and / or prevention of HBV infections.SELECTED DRAWING: Figure 3

A piezoelectric plate sensor comprising a piezoelectric layer; two electrodes; and an insulation layer. The insulation layer is produced by soaking the piezoelectric layer and two electrodes in a mercaptopropyltrimethoxysilane solution with an amount of water from 0.1 v / v. % to about 1 v / v % and at pH from about 8 to about 150 for a period from about 8 to about 15 hours, and the mercaptopropyltrimethoxysilane solution has a concentration of mercaptopropyltrimethoxysilane from about 0.01 v / v % to about 0.5 v / v %. A method of detecting a biomolecule in a sample using the piezoelectric plate sensor in particular, that of detecting a genetic marker with PCR sensitivity and specificity without the need of DNA isolation or amplification is also provided. The piezoelectric plate sensor may be used to diagnose various diseases including breast cancer, myocardial infarction, diarrhea, Clostridium difficile infection, and hepatitis B infection.

This application relates to potent oligonucleotides useful for reducing HBsAg expression and treating HBV infections.

This application belongs to the field of immunoassay technology, specifically relating to specific binding proteins of hepatitis B viruses (MHBs), nucleic acid molecules, vectors, cells, detection kits, and their preparation methods and applications. This application provides a specific binding protein of MHBs with specific CDRs, exhibiting high affinity and specificity. It solves the problem in existing technologies of being unable to distinguish between large, medium, and small hepatitis B virus proteins, and ensures that the antibody does not cross-react with large and small proteins, thus improving detection specificity and avoiding false positive results. The specific binding protein of MHBs in this application can bind to a chemiluminescent detection system, thereby achieving highly sensitive detection of MHB antigen levels in clinical samples, with high consistency with nucleic acid detection results, providing an important tool for monitoring hepatitis B infection status and disease progression.

This application belongs to the field of immunoassay technology, specifically relating to LHBs-specific binding proteins, nucleic acid molecules, vectors, cells, detection kits, and their preparation methods and applications. This application provides an LHBs-specific binding protein with specific CDRs, exhibiting high affinity and specificity. It solves the problem in existing technologies of being unable to distinguish between large, medium, and small hepatitis B virus proteins, and ensures that the antibody does not cross-react with medium and small proteins, thus improving detection specificity and avoiding false positive results. The LHBs-specific binding protein of this application can bind to chemiluminescent detection systems, thereby achieving highly sensitive detection of LHBs antigen levels in clinical samples, with high consistency with nucleic acid detection results, providing an important tool for monitoring hepatitis B infection status and disease progression.

This application relates to potent oligonucleotides useful for reducing HBsAg expression and treating HBV infections.

The invention relates to a hepatitis B prevention and control big language model construction method, which realizes an intelligent response mechanism for automatically switching a health education mode or a clinical decision support mode based on user role attributes by integrating evidence-based medical knowledge related to hepatitis B prevention and control and retrieving an integrated system for enhanced generation and fine tuning, and provides a medical evidence tracing function. The accuracy and verifiability of hepatitis B prevention and control information are improved, off-line deployment on edge computing equipment is supported, and the life cycle of a model is prolonged. The problems that a general large model is inaccurate in knowledge, single in service mode, untraceable in conclusion and the like in the field of hepatitis B prevention and control medicine are solved, the accuracy, individuation and clinical credibility of hepatitis B prevention and control information are improved, and reliable evidence-based support is provided for full-period management of hepatitis B infected persons.

Provided herein are epigenetic-modifying DNA-targeting systems, such as CRISPR-Cas / guide RNA (gRNA) systems, for the transcriptional repression of Hepatitis B viral (HBV) genes to promote a cellular phenotype that leads to the reduction of HBV infection. In some embodiments, the epigenetic-modifying DNA-targeting systems bind to or target a target site of at least one gene or regulatory element thereof in a Hepatitis B viral DNA sequence in cell. In some aspects, the provided systems relate to the transcriptional repression of one or more Hepatitis B viral gene and / or regulatory element thereof. In some aspects, also provided herein are methods and uses related to the provided compositions, for example in repressing Hepatitis B viral replication and expression in connection with Hepatitis B infections.

The present invention provides a method for identifying compounds that prevent, improve, and / or suppress hepatitis B virus (HBV) infection. [Solution] The present invention relates to a method for identifying compounds that (i) reduce the expression and / or activity of PAP-related domain-containing protein 5 (PAPD5) and / or PAP-related domain-containing protein 7 (PAPD7) and / or (ii) bind to PAPD5 and / or PAPD7 and inhibit the proliferation of HBV, as compounds for preventing, improving and / or suppressing HBV infection. The present invention also provides PAPD5 and / or PAPD7 inhibitors for use in the treatment and / or prevention of HBV infection, as well as mixed formulations comprising PAPD5 inhibitors and PAPD7 inhibitors for simultaneous or sequential use in the treatment and / or prevention of HBV infection. Pharmaceutical compositions for use in the treatment and / or prevention of HBV infection, and methods for monitoring treatment outcomes during the treatment of HBV infection are also included in the present invention.

The invention belongs to the technical field of immunodetection, and particularly relates to a specific binding protein of MHBs, a nucleic acid molecule, a carrier, a cell, a detection kit and a preparation method and application thereof. The invention provides a specific binding protein of MHBs, which has specific CDRs and relatively high affinity and specificity, solves the problem that large protein, medium protein and small protein of hepatitis B virus cannot be distinguished in the prior art, ensures that an antibody is not subjected to cross reaction with the large protein and the small protein, improves the detection specificity, and reduces the detection cost. And a false positive result is avoided. The specific binding protein of the MHBs can be combined with a chemiluminescence detection system, so that high-sensitivity detection of the antigen level of the MHBs in a clinical sample is realized, the specific binding protein has high consistency with a nucleic acid detection result, and an important tool is provided for hepatitis B infection state and disease progress monitoring.

The invention belongs to the technical field of immunodetection, and particularly relates to a specific binding protein of LHBs, a nucleic acid molecule, a carrier, a cell, a detection kit and a preparation method and application thereof. The invention provides a specific binding protein of LHBs, which has specific CDRs and relatively high affinity and specificity, solves the problem that large protein, medium protein and small protein of hepatitis B virus cannot be distinguished in the prior art, ensures that an antibody is not subjected to cross reaction with the medium protein and the small protein, improves the detection specificity, and reduces the detection cost. And a false positive result is avoided. The specific binding protein of the LHBs can be combined with a chemiluminescence detection system, so that high-sensitivity detection of the antigen level of the LHBs in a clinical sample is realized, the specific binding protein has high consistency with a nucleic acid detection result, and an important tool is provided for monitoring the infection state and disease progress of hepatitis B.